Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Macrofollicular Variant of Follicular Thyroid Carcinoma: A Rare Underappreciated Pitfall in the Diagnosis of Thyroid Carcinoma.

Bongiovanni M, Sykiotis GP, La Rosa S, Bisig B, Trimech M, Missiaglia E, Gremaud M, Salvatori Chappuis V, De Vito C, Sciarra A, Foulkes WD, Pusztaszeri M.

Thyroid. 2019 Dec 30. doi: 10.1089/thy.2018.0607. [Epub ahead of print]

PMID:
31701808
2.

Acinar cell carcinoma of the pancreas with thyroid-like follicular features: first description of a new diagnostic challenging subtype.

Saglietti C, Schneider V, Bongiovanni M, Missiaglia E, Bisig B, Dorta G, Demartines N, Sempoux C, La Rosa S.

Virchows Arch. 2019 Dec;475(6):789-794. doi: 10.1007/s00428-019-02628-3. Epub 2019 Jul 23.

PMID:
31338587
3.

VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle.

Figeac N, Mohamed AD, Sun C, Schönfelder M, Matallanas D, Garcia-Munoz A, Missiaglia E, Collie-Duguid E, De Mello V, Pobbati AV, Pruller J, Jaka O, Harridge SDR, Hong W, Shipley J, Vargesson N, Zammit PS, Wackerhage H.

J Cell Sci. 2019 Jul 5;132(13). pii: jcs225946. doi: 10.1242/jcs.225946.

4.

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J.

Blood. 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549. Epub 2019 Feb 19.

PMID:
30782609
5.

MedCo: Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data.

Raisaro JL, Troncoso-Pastoriza JR, Misbach M, Sousa JS, Pradervand S, Missiaglia E, Michielin O, Ford B, Hubaux JP.

IEEE/ACM Trans Comput Biol Bioinform. 2019 Jul-Aug;16(4):1328-1341. doi: 10.1109/TCBB.2018.2854776. Epub 2018 Jul 13.

PMID:
30010584
6.

Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma.

Letourneau A, Maerevoet M, Milowich D, Dewind R, Bisig B, Missiaglia E, de Leval L.

Virchows Arch. 2018 Oct;473(4):505-511. doi: 10.1007/s00428-018-2352-y. Epub 2018 Apr 10. No abstract available.

PMID:
29637270
7.

RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells.

Vallois D, Dupuy A, Lemonnier F, Allen G, Missiaglia E, Fataccioli V, Ortonne N, Clavert A, Delarue R, Rousselet MC, Fabiani B, Llamas-Gutierrez F, Ogawa S, Thome M, Ko YH, Kataoka K, Gaulard P, de Leval L.

Haematologica. 2018 Aug;103(8):e360-e363. doi: 10.3324/haematol.2017.186767. Epub 2018 Mar 15. No abstract available.

8.

Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Voruz S, Martins F, Cairoli A, Naveiras O, Homicsko K, Missiaglia E, de Leval L, Bisig B, Michielin O, Blum S.

Haematologica. 2018 Mar;103(3):e130. doi: 10.3324/haematol.2017.186932. No abstract available.

9.

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, Michielin O, Blum S.

Haematologica. 2018 Jan;103(1):e39-e41. doi: 10.3324/haematol.2017.179150. Epub 2017 Nov 2. No abstract available.

10.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

11.

Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.

Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, Scourzic L, Dupuy A, Fataccioli V, Pujals A, Parrens M, Le Bras F, Rousset T, Picquenot JM, Martin N, Haioun C, Delarue R, Bernard OA, Delorenzi M, de Leval L, Gaulard P.

Haematologica. 2017 Apr;102(4):e148-e151. doi: 10.3324/haematol.2016.158428. Epub 2017 Jan 12. No abstract available.

12.

MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.

Missiaglia E, Shepherd CJ, Aladowicz E, Olmos D, Selfe J, Pierron G, Delattre O, Walters Z, Shipley J.

Cancer Lett. 2017 Jan 28;385:251-260. doi: 10.1016/j.canlet.2016.10.011. Epub 2016 Oct 29.

13.

Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.

Roberti A, Dobay MP, Bisig B, Vallois D, Boéchat C, Lanitis E, Bouchindhomme B, Parrens MC, Bossard C, Quintanilla-Martinez L, Missiaglia E, Gaulard P, de Leval L.

Nat Commun. 2016 Sep 7;7:12602. doi: 10.1038/ncomms12602.

14.

Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.

Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, Martin A, Bonnet C, Michielin O, Jais JP, Figeac M, Bernard OA, Delorenzi M, Haioun C, Tournilhac O, Thome M, Gascoyne RD, Gaulard P, de Leval L.

Blood. 2016 Sep 15;128(11):1490-502. doi: 10.1182/blood-2016-02-698977. Epub 2016 Jul 1.

15.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.

Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.

16.

The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.

Mohamed A, Sun C, De Mello V, Selfe J, Missiaglia E, Shipley J, Murray GI, Zammit PS, Wackerhage H.

J Pathol. 2016 Sep;240(1):3-14. doi: 10.1002/path.4745.

17.

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Hingorani P, Missiaglia E, Shipley J, Anderson JR, Triche TJ, Delorenzi M, Gastier-Foster J, Wing M, Hawkins DS, Skapek SX.

Clin Cancer Res. 2015 Oct 15;21(20):4733-9. doi: 10.1158/1078-0432.CCR-14-3326.

18.

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

19.

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.

Schell MJ, Yang M, Missiaglia E, Delorenzi M, Soneson C, Yue B, Nebozhyn MV, Loboda A, Bloom G, Yeatman TJ.

Clin Cancer Res. 2016 Feb 1;22(3):734-45. doi: 10.1158/1078-0432.CCR-15-0143. Epub 2015 Oct 7.

20.

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, Martin A, Fabiani B, Delarue R, Tournilhac O, Delorenzi M, Gaulard P, de Leval L.

Blood. 2014 Nov 6;124(19):2983-6. doi: 10.1182/blood-2014-07-584953. Epub 2014 Sep 15.

PMID:
25224410
21.

The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.

Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, Judson RN, Thway K, Nadal G, Selfe JL, Murray G, Calogero RA, De Bari C, Zammit PS, Delorenzi M, Wagers AJ, Shipley J, Wackerhage H, Camargo FD.

Cancer Cell. 2014 Aug 11;26(2):273-87. doi: 10.1016/j.ccr.2014.05.029. Epub 2014 Jul 31.

22.

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2014 Oct;25(10):1995-2001. doi: 10.1093/annonc/mdu275. Epub 2014 Jul 23.

PMID:
25057166
23.

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.

Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J, Shipley J.

Oncogene. 2014 Feb 27;33(9):1148-57. doi: 10.1038/onc.2013.46. Epub 2013 Feb 25.

24.

Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.

Ehnman M, Missiaglia E, Folestad E, Selfe J, Strell C, Thway K, Brodin B, Pietras K, Shipley J, Östman A, Eriksson U.

Cancer Res. 2013 Apr 1;73(7):2139-49. doi: 10.1158/0008-5472.CAN-12-1646. Epub 2013 Jan 21.

25.

Mpn1, mutated in poikiloderma with neutropenia protein 1, is a conserved 3'-to-5' RNA exonuclease processing U6 small nuclear RNA.

Shchepachev V, Wischnewski H, Missiaglia E, Soneson C, Azzalin CM.

Cell Rep. 2012 Oct 25;2(4):855-65. doi: 10.1016/j.celrep.2012.08.031. Epub 2012 Sep 27.

26.

HES6 enhances the motility of alveolar rhabdomyosarcoma cells.

Wickramasinghe CM, Domaschenz R, Amagase Y, Williamson D, Missiaglia E, Shipley J, Murai K, Jones PH.

Exp Cell Res. 2013 Jan 1;319(1):103-12. doi: 10.1016/j.yexcr.2012.08.010. Epub 2012 Sep 14.

PMID:
22982728
27.

Inconvenience of convenience cohorts--letter.

Williamson D, Missiaglia E, Chisholm J, Shipley J.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1388. doi: 10.1158/1055-9965.EPI-12-0724. Epub 2012 Jun 26. No abstract available.

28.

PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, Delattre O, Delorenzi M, Shipley J.

J Clin Oncol. 2012 May 10;30(14):1670-7. doi: 10.1200/JCO.2011.38.5591. Epub 2012 Mar 26.

PMID:
22454413
29.

Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.

Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, Purgato S, Missiaglia E, Tortori A, Renshaw J, Astolfi A, Taylor KR, Serravalle S, Bishop R, Nanni C, Valentijn LJ, Faccini A, Leuschner I, Formica S, Reis-Filho JS, Ambrosini V, Thway K, Franzoni M, Summersgill B, Marchelli R, Hrelia P, Cantelli-Forti G, Fanti S, Corradini R, Pession A, Shipley J.

Clin Cancer Res. 2012 Feb 1;18(3):796-807. doi: 10.1158/1078-0432.CCR-11-1981. Epub 2011 Nov 7.

30.

MFG-E8/lactadherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cells.

Carrascosa C, Obula RG, Missiaglia E, Lehr HA, Delorenzi M, Frattini M, Rüegg C, Mariotti A.

Oncogene. 2012 Mar 22;31(12):1521-32. doi: 10.1038/onc.2011.356. Epub 2011 Aug 15.

PMID:
21841820
31.

Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours.

Gilbert DC, Chandler I, Summersgill B, McIntyre A, Missiaglia E, Goddard NC, Huddart RA, Shipley J.

Int J Androl. 2011 Aug;34(4 Pt 2):e114-21; discussion e121. doi: 10.1111/j.1365-2605.2011.01161.x. Epub 2011 May 25.

PMID:
21615418
32.

Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas.

Thway K, Selfe J, Missiaglia E, Fisher C, Shipley J.

J Clin Pathol. 2011 Jul;64(7):587-91. doi: 10.1136/jclinpath-2011-200071. Epub 2011 Apr 14.

PMID:
21493758
33.

Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.

Martins AS, Olmos D, Missiaglia E, Shipley J.

Sarcoma. 2011;2011:209736. doi: 10.1155/2011/209736. Epub 2011 Mar 3.

34.

Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse.

Gilbert DC, McIntyre A, Summersgill B, Missiaglia E, Goddard NC, Chandler I, Huddart RA, Shipley J.

Genes Chromosomes Cancer. 2011 Mar;50(3):186-95. doi: 10.1002/gcc.20843. Epub 2010 Dec 16.

PMID:
21213372
35.

Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.

Zibat A, Missiaglia E, Rosenberger A, Pritchard-Jones K, Shipley J, Hahn H, Fulda S.

Oncogene. 2010 Dec 2;29(48):6323-30. doi: 10.1038/onc.2010.368. Epub 2010 Sep 6.

PMID:
20818440
36.

MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas.

Missiaglia E, Shepherd CJ, Patel S, Thway K, Pierron G, Pritchard-Jones K, Renard M, Sciot R, Rao P, Oberlin O, Delattre O, Shipley J.

Br J Cancer. 2010 Jun 8;102(12):1769-77. doi: 10.1038/sj.bjc.6605684. Epub 2010 May 25.

37.

Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells.

Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J, Lodish HF.

FASEB J. 2010 Sep;24(9):3427-37. doi: 10.1096/fj.09-150698. Epub 2010 May 13.

38.

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O.

J Clin Oncol. 2010 May 1;28(13):2151-8. doi: 10.1200/JCO.2009.26.3814. Epub 2010 Mar 29.

PMID:
20351326
39.

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A.

J Clin Oncol. 2010 Jan 10;28(2):245-55. doi: 10.1200/JCO.2008.21.5988. Epub 2009 Nov 16.

40.

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.

Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, Koster J, Summersgill B, Messahel B, Versteeg R, Pritchard-Jones K, Kool M, Shipley J.

Genes Chromosomes Cancer. 2009 Jun;48(6):455-67. doi: 10.1002/gcc.20655.

PMID:
19235922
41.

Genomic copy number and expression patterns in testicular germ cell tumours.

McIntyre A, Summersgill B, Lu YJ, Missiaglia E, Kitazawa S, Oosterhuis JW, Looijenga LH, Shipley J.

Br J Cancer. 2007 Dec 17;97(12):1707-12. Epub 2007 Dec 4.

42.

Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors.

Dalai I, Missiaglia E, Barbi S, Butturini G, Doglioni C, Falconi M, Scarpa A.

Neoplasia. 2007 Mar;9(3):181-3.

43.

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, Ferdeghini M, Pederzoli P, Scarpa A, Falconi M.

Endocr Relat Cancer. 2006 Dec;13(4):1213-21.

PMID:
17158766
44.

MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior.

Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM.

J Clin Oncol. 2006 Oct 10;24(29):4677-84. Epub 2006 Sep 11.

PMID:
16966691
45.

Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway.

Missiaglia E, Donadelli M, Palmieri M, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR.

Oncogene. 2005 Jan 6;24(1):199-211.

PMID:
15637593
46.

Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis.

Missiaglia E, Blaveri E, Terris B, Wang YH, Costello E, Neoptolemos JP, Crnogorac-Jurcevic T, Lemoine NR.

Int J Cancer. 2004 Oct 20;112(1):100-12.

47.

Allelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11.

Moore PS, Missiaglia E, Beghelli S, Bragantini E, Mina MM, Zamboni G, Falconi M, Scarpa A.

J Cancer Res Clin Oncol. 2004 Jun;130(6):339-45. Epub 2004 Mar 16.

PMID:
15024645
48.

Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine.

Cecconi D, Astner H, Donadelli M, Palmieri M, Missiaglia E, Hamdan M, Scarpa A, Righetti PG.

Electrophoresis. 2003 Dec;24(24):4291-303.

PMID:
14679576
49.

Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.

Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, Costello E, Neoptolemos JP, Lemoine NR.

J Pathol. 2003 Sep;201(1):63-74.

PMID:
12950018
50.

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.

Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F.

Am J Hematol. 2002 Sep;71(1):1-6.

Supplemental Content

Loading ...
Support Center